Edoxacord is an oral anticoagulant with edoxaban, used to prevent stroke in atrial fibrillation and treat or prevent DVT and pulmonary embolism.
We deliver to:
🇦🇺 Australia
🇨🇦 Canada
🇨🇿 Czechia
🇩🇰 Denmark🇪🇪 Estonia
🇮🇪 Ireland
🇮🇱 Israel
🇮🇹 Italy
🇯🇵 Japan
🇲🇽 Mexico
🇵🇱 Poland
🇰🇷 South Korea
🇨🇠Switzerland
🇬🇧 United Kingdom
🇺🇸 United States of Americaand more
Please note: The product packaging may vary from the images shown. The contents, ingredients, and quality of the product remain unchanged.
Edoxacord film-coated tablets 30 mg 30 pieces
$39.68
Edoxacord is an antithrombotic agent. A direct factor Xa inhibitor for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NAF) and one or more risk factors such as congestive heart failure, hypertension, diabetes mellitus, history of stroke or transient ischemic attack (TIA), age 75 years and older.
For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for the prevention of recurrent DVT and PE in adults.
Composition
- 1 tablet contains edoxaban (in the form of tosylate monohydrate) 30 mg;
- Excipients: mannitol (E 421); pregelatinized starch; crospovidone; hydroxypropylcellulose; magnesium stearate;
- shell: Opadry II Pink 32F240010: hypromellose (hydroxypropylmethylcellulose); lactose monohydrate; polyethylene glycol (macrogol); titanium dioxide (E 171); iron oxide red (E 172);
Contraindication
Hypersensitivity to the active substance or to any of the excipients of the medicinal product.
Clinically significant active bleeding.
Liver diseases accompanied by coagulopathy and clinically significant risk of bleeding.
Method of application
Prevention of stroke and systemic embolism – the recommended dose is 60 mg of edoxaban once daily.
Edoxaban therapy in patients with NPF is carried out over a long period of time.
Treatment of DVT and PE, and prevention of recurrent DVT and PE (VTE) – the recommended dose is 60 mg edoxaban once daily after initial parenteral anticoagulant administration for at least 5 days. Edoxaban and parenteral anticoagulant should not be used concomitantly.
Application features
Risk of bleeding
Edoxaban increases the risk of bleeding and may cause severe, potentially life-threatening bleeding. As with other anticoagulants, edoxaban should be used with caution in patients with conditions that put them at increased risk of bleeding. In the event of serious bleeding, the drug should be discontinued.
Pregnant women
The drug Edoxacord is contraindicated for use during pregnancy.
Children
The safety and efficacy of this medicine in children and adolescents under 18 years of age have not been established.
Drivers
The drug Edoxacord has no or little effect on the reaction speed when driving vehicles or using other mechanisms.
Overdose
Overdose of edoxaban may lead to bleeding. Experience with overdose is very limited.
Side effects
From the blood and lymphatic system: anemia, thrombocytopenia.
On the part of the immune system: anaphylactic reactions, allergic edema, hypersensitivity.
Nervous system: dizziness, headache, intracranial hemorrhage, subarachnoid hemorrhage.
From the organs of vision: ocular hemorrhage, conjunctival/scleral hemorrhages.
On the part of the heart: hemorrhage into the pericardial cavity.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children.
You may also like
